Search

for
Search:

Loop diuretics may double bone loss in elderly men, finasteride lowers prostate cancer risk but may increase high-grade tumors, abarelix reduces testosterone quickly, and transdermal testosterone offers minimal sexual benefit for women.

research Finasteride plus doxazosin combination tops in BPH

August 2002 in “Inpharma Weekly”

research Highlights from JAAD Reviews: August 2025—Bicalutamide for female hair loss

May 2025 in “Journal of the American Academy of Dermatology”

Bicalutamide shows promise for treating female hair loss.

research Finasteride.

January 2011 in “Bloomsbury Academic eBooks”

research 0478 Outcomes of oral dutasteride and oral minoxidil for treating endocrine therapy-induced alopecia from breast cancer treatment: A case series

July 2025 in “Journal of Investigative Dermatology”

research FINASTERIDE AND PSA

November 2005 in “The Journal of Urology”

research [A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine].

March 2007

The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.

research Bicalutamide and the new perspectives for female pattern hair loss treatment: What dermatologists should know

3 citations , January 2022 in “Journal of Cosmetic Dermatology”

Bicalutamide, a drug with a good safety profile, is a promising new treatment for female pattern hair loss.

research 17-Oximino-5-androsten-3β-yl esters: synthesis, antiproliferative activity, acute toxicity, and effect on serum androgen level

7 citations , August 2010 in “Medicinal Chemistry Research”

Some synthesized compounds were more effective than Finasteride in reducing prostate cancer cell growth and androgen levels.

research 5α-Reductase inhibitors in androgenetic alopecia

January 2015 in “Current Opinion in Endocrinology, Diabetes and Obesity”

research Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome

7 citations , September 2023 in “Cancer Treatment Reviews”

Managing side effects of endocrine therapy is crucial to improve adherence and survival in breast cancer patients.

research Cystitis Due to Cytoxan: Case Report

15 citations , May 1966 in “The Journal of Urology”

A woman developed severe bladder inflammation after cancer treatment with Cytoxan.

research Prolonged remissions of metastatic breast cancer achieved with a six-drug regimen of relatively low toxicity

6 citations , June 1983 in “Cancer”

A six-drug treatment for metastatic breast cancer showed promising results with low side effects, especially in premenopausal women.

research America - A Diversity of Life Styles.

January 1975 in “NJEA Review”

The drug showed promise in treating renal cell carcinoma with manageable side effects.

research Computational Evaluation of Dibenzo Compounds as Potential Dual Inhibitors of Androgen Receptor and 5α-Reductase

January 2022 in “Asian journal of Current Research in Clinical Cancer”

Some dibenzo compounds might help treat cancer with fewer side effects.

research Calcipotriol/dithranol

March 2019 in “Reactions Weekly”

research Health Canada has approved finasteride [Proscar; Merck Frosst] and doxazosin cotherapy

September 2004 in “Inpharma Weekly”

research Mesotherapy with bicalutamide for female pattern hair loss

September 2024 in “Indian Journal of Dermatology Venereology and Leprology”

Mesotherapy with bicalutamide has limited effectiveness for female hair loss.

Bicalutamide 25 Mg Associated With Minoxidil 1 Mg Versus Minoxidil 1 Mg for Female-Pattern Hair Loss: A Randomized Double-Blind Clinical Trial

research Bicalutamide 25 mg associated with minoxidil 1 mg versus minoxidil 1 mg for female-pattern hair loss: A randomized double-blind clinical trial

January 2025 in “JAAD International”

Bicalutamide added no extra benefit over minoxidil alone for female-pattern hair loss.

Safety and Patient-Reported Outcomes in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated With CDK4/6 Inhibitors in China: A Cross-Sectional Study

research Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study.

June 2024 in “Journal of Clinical Oncology”

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

research The selective androgen receptor modulator GTx‐024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double‐blind, placebo‐controlled phase II trial

306 citations , August 2011 in “Journal of cachexia, sarcopenia and muscle”

Enobosarm significantly increased muscle mass and improved physical function in elderly men and postmenopausal women without serious side effects.

Smoothened Receptor Inhibitor Vismodegib for the Treatment of Basal Cell Carcinoma: A Retrospective Analysis of Efficacy and Side Effects

research Smoothened receptor inhibitor vismodegib for the treatment of basal cell carcinoma: a retrospective analysis of efficacy and side effects

8 citations , May 2019 in “Journal of dermatological treatment”

Vismodegib is effective for basal cell carcinoma but has severe side effects.

research Response to “Improvement of female pattern hair loss with bicalutamide: a time-dependent process”

August 2025 in “JAAD International”

Bicalutamide may take longer to work for female hair loss, and higher doses might be needed.

← Previous page Next page →